Clinical Utilities
Myasthenia gravis (MG), the most common neuromuscular transmission disorder, is an antibody-mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. A small portion of patients with early onset or ocular restricted MG may only have AChR modulating autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulating autoantibodies should be ordered. AChR blocking autoantibodies are directed against the neurotransmitter-binding site and may be the only AChR autoantibody in about 1% of MG patients.

CPT Codes
83519

The CPT codes provided are based on AMA guidelines
and are for informational purposes only. CPT coding is the
sole responsibility of the billing party. Please direct any questions
regarding coding to the payer being billed.

Reference Range

Component Information

Name		ACHR BLOCKING AUTOANTIBODIES
Method		RIA
CPT Code		83519
Units		%
Ref Range		Less than 15
Reflex Reason

Collection Notes

Additional Comments